Compare iShares MSCI India ETF (INDA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI India ETF trades at $47.74 (market cap $5.71B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares MSCI India ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 60 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| INDA | TVTX | |
|---|---|---|
Market Cap | $5.71B | $4.88B |
Volume | 3,011,243 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $67.52 |
52-Week Low | $45.42 | $26.79 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $47.24, up 1.99% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Recent news highlights India's energy security concerns and IT sector weakness, creating a cautious market environment despite the country's economic growth narrative.
The outlook remains cautious with technical weakness outweighing short-term gains. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy sector instability, weather-dependent agricultural output, and global trade tensions affecting key export industries.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
